Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Pre-Clinical Study on the Dual BCL2/BCL-XL Inhibitor AZD0466 for the Treatment of Chronic Lymphocytic Leukemia

Billy Jebaraj, Rashmi Priyadharshini Dheenadayalan, Annika Müller, Jialei Qi, Eugen Tausch, Christof Schneider, Daniela Steinbrecher, Daniel Mertens, Felix Seyfried, Lüder Hinrich Meyer, André Lechel, Barbara F. Eichhorst, Courtney L Andersen, Giulia Fabbri, Stephan Stilgenbauer

Blood (2023) 142 (Supplement 1): 84.

https://doi.org/10.1182/blood-2023-188554

Published: 2023

Journal Articles

Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy

Jialei Qi, Sascha Endres, Deyan Yordanov Yosifov, Eugen Tausch, Rashmi Priyadharshini Dheenadayalan, Xiang Gao, Annika Scheffold, Felix Seyfried, Lüder Meyer, Christof Schneider, Daniel Mertens, Peter Gierschik, Martin Wist, Stephan Stilgenbauer, Billy Michael Chelliah Jebaraj

Blood (2022) 140 (Supplement 1): 3139–3141.

https://doi.org/10.1182/blood-2022-159427

Published: 2022

Journal Articles

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Blood (2022) 140 (Supplement 1): 839–841.

https://doi.org/10.1182/blood-2022-163775

Published: 2022

Journal Articles

NOTCH1 Signaling Is Dysregulated in CLL By the Deubiquitinase USP28 That Is Recurrently Affected By Del(11q) and Can be Therapeutically Targeted

Alena Sophie Ehrmann, Miguel Quijada Álamo, Viola Close, Min Guo, Claudia Pérez Carretero, Luis A Corchete, Eugen Tausch, Christof Schneider, Hartmut Döhner, Stephan Stilgenbauer, Franz Oswald, Jesus Maria Hernández-Rivas, Daniel Mertens

Blood (2022) 140 (Supplement 1): 4100–4102.

https://doi.org/10.1182/blood-2022-158168

Published: 2022

Journal Articles

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

Billy Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan, Sascha Endres, Philipp M. Roessner, Felix Seyfried, Claudia Walliser, Martin Wist, Jialei Qi, Eugen Tausch, Daniel Mertens, Judith A. Fox, Klaus-Michael Debatin, Lüder Hinrich Meyer, Pietro Taverna, Martina Seiffert, Peter Gierschik, Stephan Stilgenbauer

Blood (2022) 139 (6): 859–875.

https://doi.org/10.1182/blood.2021011516

Published: 2022

Includes: Supplemental data

Journal Articles

Triggering T-cell activity in CLL

Daniel Mertens, Jan Krönke

Blood (2021) 137 (2): 150–151.

https://doi.org/10.1182/blood.2020009360

Published: 2021

Journal Articles

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-141552

Published: 2020

Journal Articles

Robust Discovery of Candidate DNA Methylation Cancer Drivers

Heng Pan, PhD, Loïc Renaud, MD MSc, Ronan Chaligne, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Daniel Mertens, PhD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Chao Zhang, PhD, Doron Betel, PhD, Andreas Gnirke, Marcin Imielinski, Jerome Moreaux, PhD, Michael Hallek, Alexander Meissner, PhD, Stephan Stilgenbauer, MD, Catherine J. Wu, MD, Olivier Elemento, PhD, Dan A. Landau, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136830

Published: 2020

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

Journal Articles

Telomere Shortening By Terc Knockout in the Eµ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, PhD, André Lechel, Sarah-Fee Katz, PhD, Eugen Tausch, Johannes Bloehdorn, MD, Daniela Steinbrecher, PhD, Vanni Torresi, Christof Schneider, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Lenhard Rudolph, Stephan Stilgenbauer

Blood (2019) 134 (Supplement_1): 1732.

https://doi.org/10.1182/blood-2019-126878

Published: 2019

Journal Articles

Modelling Single Cell B-Cell Receptor Signaling Reveals Enhanced Activity in Primary CLL Cells Compared to Non-Malignant Cells While Fundamental Network Circuit Topology Remains Stable Even with Novel Therapeutic Inhibitors

Daniel Mertens, PhD, Christine Wolf, PhD, Carsten Maus, PhD, Michael Persicke, Katharina Filarsky, PhD, Hartmut Döhner, Peter Lichter, PhD, Thomas Höfer, PhD, Stephan Stilgenbauer, MD

Blood (2019) 134 (Supplement_1): 4275.

https://doi.org/10.1182/blood-2019-127837

Published: 2019

Journal Articles

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Blood (2019) 134 (6): 534–547.

https://doi.org/10.1182/blood.2018881029

Published: 2019

Includes: Supplemental data

Journal Articles

FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL

Viola Close, William Close, Sabrina Julia Kugler, Michaela Reichenzeller, Deyan Yordanov Yosifov, Johannes Bloehdorn, Leiling Pan, Eugen Tausch, Mike-Andrew Westhoff, Hartmut Döhner, Stephan Stilgenbauer, Franz Oswald, Daniel Mertens

Blood (2019) 133 (8): 830–839.

https://doi.org/10.1182/blood-2018-09-874529

Published: 2019

Includes: Supplemental data

Journal Articles

Modeling of the Epigenome of the Cell-of-Origin Identifies Cancer-Specific DNA Methylation Patterns in CLL

Justyna Anna Wierzbinska, Reka Toth, Naveed Ishaque, Jan-Phillip Mallm, Karsten Rippe, Daniel Mertens, Thomas Hielscher, Thorsten Zenz, MD, Marc Seifert, Ralf Küppers, Yassen Assenov, Stephan Stilgenbauer, John C. Byrd, MD, Christopher C. Oakes, Daniel B. Lipka, Christoph Plass

Blood (2018) 132 (Supplement 1): 3885.

https://doi.org/10.1182/blood-2018-99-115941

Published: 2018

Journal Articles

Recurrent Mutations in EGR2 Direct Specific Epigenetic Reconfiguration in Chronic Lymphocytic Leukemia

Blood (2018) 132 (Supplement 1): 650.

https://doi.org/10.1182/blood-2018-99-119070

Published: 2018

Journal Articles

NOTCH1 Signaling Is Activated in CLL By Mutations of FBXW7 and Low Expression of USP28 at 11q23

Viola Close, MSc, William Close, MSc, Sabrina Julia Kugler, PhD, Michaela Reichenzeller, PhD, Deyan Yordanov Yosifov, PhD, Johannes Bloehdorn, MD, Leiling Pan, MSc, Eugen Tausch, MD, Mike-Andrew Westhoff, PhD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD, Franz Oswald, PhD, Daniel Mertens

Blood (2018) 132 (Supplement 1): 946.

https://doi.org/10.1182/blood-2018-99-114491

Published: 2018

Journal Articles

MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy

Johannes Bloehdorn, MD, Julia Krzykalla, MSc, Billy Michael Chelliah Jebaraj, PhD, Karlheinz Holzmann, Dr. rer. nat., Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Kathryn Humphrey, Michael Wenger, Eugen Tausch, MD, Christof Schneider, MD, Lars Bullinger, MD, Kirsten Fischer, MD, Michael Hallek, MD, Daniel Mertens, Axel Benner, Hartmut Döhner, MD, Stephan Stilgenbauer

Blood (2018) 132 (Supplement 1): 1866.

https://doi.org/10.1182/blood-2018-99-116937

Published: 2018

Journal Articles

High-Resolution SNP-Array Profiling of "Ultra-High Risk" CLL Cases Reveals New Recurrent Genomic Alterations

Jennifer Edelmann, MD PhD, Karlheinz Holzmann, Dr. rer. nat., Eugen Tausch, MD, Anna Dolnik, PhD, Tamara J. Blätte, MSc, Stefan Ibach, Dr, Jenny Saub, Daniel Mertens, PhD, Lars Bullinger, MD, Kirsten Fischer, MD, Valentin Goede, MD, John G. Gribben, MDDSc FMedSci, Michael J. Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 2992.

https://doi.org/10.1182/blood.V130.Suppl_1.2992.2992

Published: 2017

Journal Articles

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Annika Scheffold, Billy Michael Chelliah Jebaraj, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 390.

https://doi.org/10.1182/blood.V130.Suppl_1.390.390

Published: 2017

Journal Articles

Ibrutinib-resistant CLL: unwanted and unwonted!

Daniel Mertens, Stephan Stilgenbauer

Blood (2017) 129 (11): 1407–1409.

https://doi.org/10.1182/blood-2017-01-761536

Published: 2017

NARROW

Pre-Clinical Study on the Dual BCL2/BCL-XL Inhibitor AZD0466 for the Treatment of Chronic Lymphocytic Leukemia

Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

NOTCH1 Signaling Is Dysregulated in CLL By the Deubiquitinase USP28 That Is Recurrently Affected By Del(11q) and Can be Therapeutically Targeted

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

Triggering T-cell activity in CLL

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Robust Discovery of Candidate DNA Methylation Cancer Drivers

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Telomere Shortening By Terc Knockout in the Eµ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival

Modelling Single Cell B-Cell Receptor Signaling Reveals Enhanced Activity in Primary CLL Cells Compared to Non-Malignant Cells While Fundamental Network Circuit Topology Remains Stable Even with Novel Therapeutic Inhibitors

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL

Modeling of the Epigenome of the Cell-of-Origin Identifies Cancer-Specific DNA Methylation Patterns in CLL

Recurrent Mutations in EGR2 Direct Specific Epigenetic Reconfiguration in Chronic Lymphocytic Leukemia

NOTCH1 Signaling Is Activated in CLL By Mutations of FBXW7 and Low Expression of USP28 at 11q23

MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy

High-Resolution SNP-Array Profiling of "Ultra-High Risk" CLL Cases Reveals New Recurrent Genomic Alterations

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Ibrutinib-resistant CLL: unwanted and unwonted!

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only